Download PDF

Journal of Biomedical Science

, Volume 13, Issue 6, pp 825–832 | Cite as

Expression of cyclooxygenase-2 related to angiogenesis in uterine cervical cancers

  • Jiro Fujimoto
  • Hiroshi Toyoki
  • Eriko Sato
  • Hideki Sakaguchi
  • Israt Jahan
  • Syed Mahfuzul Alam
  • Teruhiko Tamaya
Article
First Online:
Received:
Accepted:

Summary

Angiogenesis is essential for development, growth and advancement of solid tumors. Cyclooxygenase (COX)-2 is recognized as an angiogenic factor in various tumors. This prompted us to study the clinical implications of COX-2 expression related to angiogenesis in uterine cervical cancers. There was a significant correlation between microvessel counts and COX-2 levels in uterine cervical cancers. COX-2 localized in the cancer cells, but not in the stromal cells of uterine cervical cancer tissues. COX-2 levels increased with advancement, and the prognosis of the 30 patients with high COX-2 expression in uterine cervical cancers was poor (60%), while the 24-month survival rate of the other 30 patients with low COX-2 expression was 90%. Furthermore, COX-2 levels significantly correlated with VEGF levels in uterine cervical cancers. VEGF associated with COX-2 might work on angiogenesis in advancement. Therefore, long-term administration of COX-2 inhibitors might be effective on the suppression of regrowth or recurrence after intensive treatment for advanced uterine cervical cancers.

Keywords

COX-2 VEGF angiogenesis uterine cervical cancer 
Download to read the full article text

Notes

Acknowledgements

The authors wish to thank Mr. John Cole for proofreading the English of this manuscript.

References

  1. 1.
    Folkman J. (1985). Tumor angiogenesis. Adv. Cancer Res. 43: 175–203PubMedCrossRefGoogle Scholar
  2. 2.
    Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., Tamaya T. (1999). Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br. J. Cancer 80: 827–833PubMedCrossRefGoogle Scholar
  3. 3.
    Fujimoto J., Toyoki H., Sato E., Sakaguchi H., Tamaya T. (2004) Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br. J. Cancer 91: 466–469PubMedCrossRefGoogle Scholar
  4. 4.
    Fujimoto J., Ichigo, S., Hirose R., Sakaguchi H. and Tamaya T. (1998) Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Cancer Lett. 134:15–22PubMedCrossRefGoogle Scholar
  5. 5.
    Fujimoto J., Sakaguchi H., Hirose R., Ichigo S. and Tamaya T. (1988) Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83: 2528–2533CrossRefGoogle Scholar
  6. 6.
    Fujimoto J., Sakaguchi H., Aoki I., Khatun S., Tamaya T. (2001). Clinical implications of the expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br. J. Cancer 85: 313–316PubMedCrossRefGoogle Scholar
  7. 7.
    Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., Tamaya T. (1999). The expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine cervical cancers. Br. J. Cancer 79:1249–1254PubMedCrossRefGoogle Scholar
  8. 8.
    Fujimoto J., Sakaguchi H., Hirose R., Wen H., Tamaya T. (1999) Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers. Cancer Res. 59: 3041–3044PubMedGoogle Scholar
  9. 9.
    Fujimoto J., Sakaguchi H., Aoki I., Tamaya T. (2000) The value of platelet-derived endothelial cell growth factor as a novel predictor of advancement of uterine cervical cancers. Cancer Res. 60: 3662–3665PubMedGoogle Scholar
  10. 10.
    Fujimoto J., Ichigo S., Sakaguchi H., Hirose R., Tamaya T. (1998). Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Cancer Lett. 130: 115–120PubMedCrossRefGoogle Scholar
  11. 11.
    Fujimoto J., Ichigo S., Sakaguchi H., Hirose R., Tamaya T. (1998). Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in ovarian cancers. Cancer Lett. 126: 83–88PubMedCrossRefGoogle Scholar
  12. 12.
    Fujimoto J., Sakaguchi H., Aoki I., Tamaya T. (2000) Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res. 60:2632–2635PubMedGoogle Scholar
  13. 13.
    Fujimoto J., Aoki I., Khatun S., Toyoki H., Tamaya T. (2002). Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers. Ann. Oncol. 13:430–434PubMedCrossRefGoogle Scholar
  14. 14.
    Fujimoto J., Ichigo S., Hori M., Hirose R., Sakaguchi H., Tamaya T. (1997). Expression of basic fibroblast growth factor and its mRNA in advanced uterine cervical cancers. Cancer Lett. 111: 21–26PubMedCrossRefGoogle Scholar
  15. 15.
    Fujimoto J., Hori M., Ichigo S., Tamaya T. (1995). Expression of basic fibroblast growth factor and its mRNA in uterine endometrial cancers. Invas. Metast. 15: 203–210Google Scholar
  16. 16.
    Fujimoto J., Ichigo S., Hori M., Hirose R., Sakaguchi H., Tamaya T. (1997). Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. Eur. J. Gynaecol. Oncol. 18: 349–352PubMedGoogle Scholar
  17. 17.
    Fujimoto J., Aoki I., Toyoki H., Khatun S., Tamaya T. (2002). Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Ann. Oncol. 13: 1598–1604PubMedCrossRefGoogle Scholar
  18. 18.
    Fujimoto J., Aoki I., Toyoki H., Khatun S., Tamaya T. (2002) Clinical implications of expression of ETS-1 related to angiogenesis in uterine endometrial cancers. Ann. Oncol. 13: 1605–1611PubMedCrossRefGoogle Scholar
  19. 19.
    Khatun S., Fujimoto J., Toyoki H. and Tamaya T. (2003) Clinical implication of expression of ETS-1 in relation to angiogenesis in ovarian cancers. Cancer Sci. 94: 769–773PubMedCrossRefGoogle Scholar
  20. 20.
    Fujimoto J., Aoki I., Toyoki H., Khatun S., Sato E., Sakaguchi H. and Tamaya T. (2004). Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. Oncology 66: 420–428PubMedCrossRefGoogle Scholar
  21. 21.
    Ali-Fehmi R., Che M., Khalifeh I., Malone J.M., Morris R., Lawrence W.D. and Munkarah A.R. (2003) The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98: 1423–1429PubMedCrossRefGoogle Scholar
  22. 22.
    Fujiwaki R., Iida K., Kanasaki H., Ozaki T., Hata K., Miyazaki K. (2002) Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum. Pathol. 33: 213–219PubMedCrossRefGoogle Scholar
  23. 23.
    Davies G., Salter J., Hills M., Martin L.A., Sacks N., Dowsett M. (2003). Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin. Cancer Res. 9: 2651–2656PubMedGoogle Scholar
  24. 24.
    Joo Y.E., Rew J.S., Seo Y.H., Choi S.K., Kim Y.J., Park C.S., Kim S.J. (2003) Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J. Clin. Gastroenterol. 37: 28–33PubMedCrossRefGoogle Scholar
  25. 25.
    Miyata Y., Koga S., Kanda S., Nishikido M., Hayashi T., Kanetake H. (2003). Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin. Cancer Res. 9: 1741–1749PubMedGoogle Scholar
  26. 26.
    Gallo O., Masini E., Bianchi B., Bruschini L., Paglierani M., Franchi A. (2003) Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum. Pathol. 7: 708–714Google Scholar
  27. 27.
    Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. (1998). Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705–716PubMedCrossRefGoogle Scholar
  28. 28.
    Rochels R. (1984). Pathobiochemical aspects of corneal neovascularization. Fortschr. Med. 102: 101–102PubMedGoogle Scholar
  29. 29.
    Harada S., Nagy J.A., Sullivan K.A., Thomas K.A., Endo N., Rodan G.A., Rodan S.B. (1994). Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J. Clin. Invest. 93:2490–2496PubMedGoogle Scholar
  30. 30.
    Ben-Av P., Crofford L.J., Wilder R.L., Hla T. (1995.) Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372: 83–87PubMedCrossRefGoogle Scholar
  31. 31.
    Sunderkotter C., Steinbrink K., Goebeler M., Bhardwaj R., Sorg C. (1994). Macrophages and angiogenesis. J. Leukoc. Bio. 55: 410–422PubMedGoogle Scholar
  32. 32.
    International Federation of Obstetrics;Gynecology (FIGO) (1989). News. Int. J. Gynecol. Obstet. 28:189–193CrossRefGoogle Scholar
  33. 33.
    Bell D.A., Flotte T.J. (1982). Factor VIII related antigen in adenomatoid tumors. Cancer 50: 932–938PubMedCrossRefGoogle Scholar
  34. 34.
    Weidner N., Semple J.P., Welch W.R., Folkman J. (1991). Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. New Engl. J. Med. 324: 1–8PubMedCrossRefGoogle Scholar
  35. 35.
    McCarty K.S. Jr., Miller L.S., Cox E.B., Konrath J. and McCarty K.S. Sr., Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Pathol. Lab. Med 109:716--721, 1985PubMedGoogle Scholar
  36. 36.
    Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M., Sawada T., Onda N., Kato Y. and Sowa M. (1996). Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br. J. Cancer 73: 884–888PubMedGoogle Scholar
  37. 37.
    Bradford M.A. (1976). Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248–254PubMedCrossRefGoogle Scholar
  38. 38.
    Nishida M., Hino A., Mori K., Matsumoto T., Yoshikubo T., Ishitsuka H. (1996) Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol. Pharm. Bull. 19: 1407–1411PubMedGoogle Scholar
  39. 39.
    Kim Y.B., Kim G.E., Cho N.H., Pyo H.R., Shim S.J., Chang S.K., Park H.C., Suh C.O., Park T.K. and Kim B.S. (2002) Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95:531–539PubMedCrossRefGoogle Scholar
  40. 40.
    Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S. (2000). High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol. Oncol. 76: 320–325PubMedCrossRefGoogle Scholar
  41. 41.
    Chen Y.J., Wang L.S., Wang P.H., Lai C.R., Yen M.S., Ng H.T., Yuan C.C. (2003). High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol. Oncol. 88:379–385PubMedCrossRefGoogle Scholar
  42. 42.
    Lee J.S., Choi Y.D., Lee J.H., Nam J.H., Choi C., Lee M.C., Park C.S., Juhng S.W., Kim H.S., Min K.W. (2004). Expression of cyclooxygenase-2 in adenocarcinomas of the uterine cervix and its relation to angiogenesis and tumor growth. Gynecol. Oncol. 95: 523–529PubMedCrossRefGoogle Scholar
  43. 43.
    Kim Y.B., Kim G.E., Pyo H.R., Cho N.H., Keum K.C., Lee C.G., Seong J., Suh C.O., Park T.K. (2004). Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 60: 822–829PubMedCrossRefGoogle Scholar
  44. 44.
    Ishiko O., Sumi T., Yoshida H., Tokuyama O., Wakasa K., Haba T. and Ogita S. (2001). Cyclooxygenase-2 expression in an adenoid cystic carcinoma of the uterine cervix. Oncol. Rep. 8: 1023–1025PubMedGoogle Scholar
  45. 45.
    Berkman R.A., Merrill, M.J., Reinhold W.C., Monacci W.T., Saxena A., Clark W.C., Robertson J.T., Ali I.U., Oldfield E.H. (1993). Expression of vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91: 153–159PubMedCrossRefGoogle Scholar
  46. 46.
    Farrell C.L., Megyesi J., Del Maestro R.F. (1988). Effect of ibuprofen on tumor growth in the C6 spheroid implantation glioma model. J. Neurosurg. 68: 925–930PubMedCrossRefGoogle Scholar
  47. 47.
    Ferrandina G., Ranelletti F.O., Legge F., Lauriola L., Salutari V., Gessi M., Testa A.C., Werner U., Navarra P., Tringali G., Battaglia A., Scambia G. (2003). Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin. Cancer Res. 9: 4324–4231PubMedGoogle Scholar

Copyright information

© National Science Council Taipei 2006

Authors and Affiliations

  • Jiro Fujimoto
    • 1
  • Hiroshi Toyoki
    • 1
  • Eriko Sato
    • 1
  • Hideki Sakaguchi
    • 1
  • Israt Jahan
    • 1
  • Syed Mahfuzul Alam
    • 1
  • Teruhiko Tamaya
    • 1
  1. 1.Department of Obstetrics and GynecologyGifu University School of MedicineGifu CityJapan

Personalised recommendations